With no single headline event in focus, attention on Gilead Sciences (GILD) has centered on its recent share performance and ...
Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could ...
Zacks Investment Research on MSN
Gilead Sciences (GILD) reports next week: Wall Street expects earnings growth
Gilead Sciences (GILD) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports ...
Zacks Investment Research on MSN
Gilead Sciences, Inc. (GILD) is attracting investor attention: Here is what you should know
Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...
Gilead Sciences ( GILD) shares snapped a six-session losing streak, closing 0.56% higher at $133.64 on Thursday. The biopharmaceutical company began its downward trend on April 15, and the stock lost ...
Gilead (GILD) wraps up $7.8B Arcellx deal, gaining anito-cel therapy. Stock tests key support at $128 with oversold RSI ...
Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...
HIV franchise still drives growth, oncology M&A faces skepticism, & valuation looks cheap at ~16x P/E. Click for this GILD ...
Check out the latest Gilead Sciences Inc. (GILD) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment.
Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the September 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results